Slingshot members are tracking this event:

Celgene Announces Phase 2 Data from RADIANCE Trial of Ozanimod

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data Celgene Corporation announced the results from its 72-week RADIANCE trial of ozanimod on patients with relapsing multiple sclerosis.  "RADIANCE met its primary efficacy endpoint — reduction in the cumulative number of total gadolinium-enhancing (GdE) lesions, as determined by MRI, from week 12 to week 24."  For placebo patients switched after week 24 to either dose of ozanimod, the mean number of GdE lesions was decreased by 90 to 95 percent compared with that at week 24.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 18, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2 Data, Ozanimod, Multiple Sclerosis